Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Photonz to scale up heart drug production in Europe

Photonz to scale up heart drug production in Europe

By Peter Kerr

April 12 (BusinessDesk) - Photonz, a biotech start-up which counts Stephen Tindall as its biggest shareholder, has signed a deal with French company Separex to extract an Omega-3 fatty acid from its patented microalgae fermentation process.

Auckland-based Photonz, which won a $2.9 million TechNZ research and development grant, is ramping up production of eicosapentaenoic acid (EPA), which is claimed to help lower blood cholesterol levels when used in conjunction with statin drugs. Currently EPA is sourced from fish oil and Photonz claims its technology offers a more secure supply for the US$60 billion cardiovascular disease market.

The company is in talks with several European pharmaceutical-quality contract manufacturers to carry out scaled-up production, which will then be further refined by Separex. Photonz is aiming to turn a profit by 2014.

"EPA demand is going to outstrip supply," said chief financial officer Richard Justice. "The fisheries supply that exists today is under threat."

Fish concentrate the EPA in their own bodies from eating the sea-borne microalgae. Photonz can ferment the same algae and extract EPA direct.

Photonz has a U.S. partner to distribute EPA, and will use scaled up European production to tap into a market worth hundreds of millions of dollars a year, Justice said. Once the company becomes cash-flow positive, it will look to set up other production and concentrating facilities in New Zealand.

The TechNZ R&D grant will enable Photonz to complete its development programme, allowing full manufacturing process at industrial scale. It is the third government R&D grant the company has received.

Since its formation in 2002, it has raised $6.2 million in start up capital, and recently announced at the NZBio conference that it is seeking at least an additional $5 million to help continue its expansion.

"We're still at an early stage of product development," said Justice. "What we've done with the algae fermentation is something no one else has achieved, though there's been plenty who have been trying. We've flown under the radar of most people."

Justice said Photonz has a number of potential exit strategies. Using existing manufacturers in Europe is considered the fastest and easiest way to scale up production and profit he said.

Separex uses supercritical carbon dioxide, where the gas is maintained as a very cold liquid and acts as a solvent, to extract the EPA lipid and deliver a pharmaceutical-grade product that is identical to the fish-derived product.

(BusinessDesk)

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 


Energy Resources Aotearoa: Doubling Of Coal Use Shows Need For Local Natural Gas

New figures showing a near doubling of coal-fired electricity generation highlight New Zealand’s energy shortage and the need for natural gas as a lower carbon alternative, according to Energy Resources Aotearoa... More>>


E Tu: ‘Sense Of Mourning’ As Norske Skog Mill Set To Close

Workers at Norske Skog’s Tasman Mill now know they’ll be losing their jobs in little over a month’s time.
On Wednesday afternoon, workers were told the mill will be stopping production from the end of June... More>>




Stats NZ: Card Spending Sees Strong Growth In May

Seasonally adjusted card spending rose by $189 million (2.3 percent) between April 2021 and May 2021, Stats NZ said today.
Spending rose across all industries for the first time since New Zealand moved to level 1 in June 2020... More>>




Auction: 1.4 Million In Rare Vintage Watches, Gems, Jewels & Diamonds Go Under The Hammer At Webb’s

An auction event showcasing over 1.4 Million dollars in rare jewels, gems, diamonds and vintage watches is due to take place this Sunday by Auckland based auction house Webb’s... More>>

Catalist: NZ’s New SME Stock Exchange, Gets Licence To Go Public

New Zealand has a new stock exchange – designed specifically for small and medium-sized businesses (SMEs) to raise up to $20 million a year from the public.
Called Catalist, the exchange has already been successfully working the private investment sector.... More>>

E-Commerce: Over 40% Of Those Engaged In The Bitcoin Community Are Millennials

Bitcoin has emerged to be a popular topic among millennials with digital currency increasingly being viewed as a potential source of creating wealth through investments. The interest in bitcoin by millennials signals the role this age group plays in the possible realization of the digital currency’s mass adoption... More>>